InvOpps GP IV, L.L.C. 3
3 · Oyster Point Pharma, Inc. · Filed Oct 30, 2019
Insider Transaction Report
Form 3
InvOpps GP IV, L.L.C.
Director10% Owner
Holdings
- (indirect: See Footnotes)
Series B Convertible Preferred Stock
→ Common Stock, par value $0.001 per share (609,965 underlying) - (indirect: See footnotes)
Series B Convertible Preferred Stock
→ Common Stock, par value $0.001 per share (1,230,050 underlying)
Footnotes (5)
- [F1]These shares of Series B Convertible Preferred Stock will automatically be converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock has no expiration date.
- [F2]Securities directly held by InvOpps IV US, L.P. ("Invus IV US").
- [F3]Securities directly held by InvOpps IV, L.P. ("Invus IV").
- [F4]InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP.
- [F5]Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.